Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.
El Maalouf
Ghassan
G
Mitry
Emmanuel
E
Lacout
Alexis
A
Lièvre
Astrid
A
Rougier
Philippe
P
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001927:Brain Diseases / Q000139:chemically induced* / Q000473:pathology*; D001933:Brain Stem / Q000473:pathology*; D003110:Colonic Neoplasms / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab